

GLAXOSMITHKLINE PLC
Form 6-K
January 15, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 15 January 2019

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E N Walmsley
Chief Executive Officer
- b) Position/status

- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

- c) Price(s) and volume(s)

| | |
|--------------------------|-----------|
| Price(s) | Volume(s) |
| £15.2875 | 1535.597 |
| n/a (single transaction) | |

- d) Aggregated information
Aggregated volume Price

- e) Date of the transaction 2019-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Vaccines

- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

| | |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 42.320 |
| Aggregated information | n/a (single transaction) |
| d) Aggregated volume Price | |
| e) Date of the transaction | 2019-01-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------------------------------------|-------------------------|
| a) Name | Mr S P Dingemans |
| b) Position/status | Chief Financial Officer |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|--|--|

| | |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 1050.550 |
| Aggregated information | n/a (single transaction) |
| d) Aggregated volume Price | |
| e) Date of the transaction | 2019-01-11 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr J Ford
 b) Position/status SVP & General Counsel
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 10
 January 2019.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.2875 0.012
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2019-01-11

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr J Ford
 b) Position/status SVP & General Counsel
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|---|
| a) Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
| b) Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) \$39.4400 75.536 |
| d) Aggregated information | n/a (single transaction) |
| e) Date of the transaction | 2019-01-11 |
| f) Place of the transaction | New York Stock Exchange (XNYS) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|------------------------------------|---------------------------------|
| a) Name | Mr N Hirons |
| b) Position/status | SVP, Global Ethics & Compliance |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 309.578 |
| d) Aggregated information | n/a (single transaction) |

Aggregated volume Price

- e) Date of the transaction 2019-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons
SVP, Global Ethics & Compliance
- b) Position/status

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053

- b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019

- c) Price(s) and volume(s)
Price(s) Volume(s)
\$39.4400 18.799
n/a (single transaction)

- d) Aggregated information
Aggregated volume Price

- e) Date of the transaction 2019-01-11
- f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
- b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| \$39.4400 | 424.074 |
| n/a (single transaction) | |
- d) Aggregated information
Aggregated volume Price
- e) Date of the transaction 2019-01-11
- f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | |
|---|--|
| | paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 1945.478 n/a (single transaction) |
| Aggregated information | |
| d) | |
| Aggregated volume Price | |
| e) Date of the transaction | 2019-01-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |
| | |
| 1. Details of PDMR/person closely associated with them ('PCA') | |
| a) Name | Mr R Simard President, Pharma Supply Chain |
| b) Position/status | |
| c) Initial notification/ amendment | Initial notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 363.181 n/a (single transaction) |
| Aggregated information | |
| d) | |
| Aggregated volume Price | |
| e) Date of the transaction | 2019-01-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, Human Resources
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
 - c) Price(s) and volume(s)

| | |
|--------------------------|-----------|
| Price(s) | Volume(s) |
| £15.2875 | 357.061 |
| n/a (single transaction) | |
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2019-01-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status President, Global Affairs
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

| | |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 210.297 |
| | n/a (single transaction) |
| d) Aggregated information | |
| | Aggregated volume Price |
| e) Date of the transaction | 2019-01-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|--------------------|--|
| a) Name | Mrs K Thomson PCA of Mr P C Thomson |
| b) Position/status | (President, Global Affairs) |

| | |
|---------------------------------------|----------------------|
| c) Initial notification/ amendment | Initial notification |
|---------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|--|--|

| | |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019. |
|------------------------------|--|

| | |
|---------------------------|--|
| c) Price(s) and volume(s) | Price(s) Volume(s) £15.2875 127.445 |
|---------------------------|--|

| | |
|---------------------------|--------------------------|
| d) Aggregated information | n/a (single transaction) |
|---------------------------|--------------------------|

| | |
|--|-------------------------|
| | Aggregated volume Price |
|--|-------------------------|

| | |
|-----------------------------|------------|
| e) Date of the transaction | 2019-01-11 |
| f) Place of the transaction | |

London Stock Exchange
(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 15, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc